Combining a pair of experimental drugs may help treat malignant peripheral nerve sheath tumors with fewer harmful side effects, according to preliminary animal studies led by investigators at the ...

A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs) - soft tissue tumors that are stubbornly resistant to chemotherapy and radiation - ...

Peripheral nerve sheath tumors (PNSTs), particularly schwannomas, are the most common type of nerve tumors. These tumors arise from the protective sheath surrounding peripheral nerves and can occur in ...

Combining a pair of experimental drugs may help treat malignant peripheral nerve sheath tumors with fewer harmful side effects, according to preliminary animal studies. Combining a pair of ...

A multicenter collaboration led by the Bellvitge Biomedical Research Institute (IDIBELL) - Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) identified a ...

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath ...

SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and ...